WO2008020596A3 - Treating or preventing cancers over-expressing reg4 or kiaa0101 - Google Patents

Treating or preventing cancers over-expressing reg4 or kiaa0101 Download PDF

Info

Publication number
WO2008020596A3
WO2008020596A3 PCT/JP2007/065873 JP2007065873W WO2008020596A3 WO 2008020596 A3 WO2008020596 A3 WO 2008020596A3 JP 2007065873 W JP2007065873 W JP 2007065873W WO 2008020596 A3 WO2008020596 A3 WO 2008020596A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
present
reg4
polypeptides
cancer
Prior art date
Application number
PCT/JP2007/065873
Other languages
French (fr)
Other versions
WO2008020596A2 (en
Inventor
Yusuke Nakamura
Hidewaki Nakagawa
Shuichi Nakatsuru
Original Assignee
Oncotherapy Science Inc
Yusuke Nakamura
Hidewaki Nakagawa
Shuichi Nakatsuru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc, Yusuke Nakamura, Hidewaki Nakagawa, Shuichi Nakatsuru filed Critical Oncotherapy Science Inc
Priority to JP2009524366A priority Critical patent/JP2010501161A/en
Priority to CA 2660516 priority patent/CA2660516A1/en
Priority to BRPI0715763 priority patent/BRPI0715763A2/en
Priority to EP07792516A priority patent/EP2059593A2/en
Publication of WO2008020596A2 publication Critical patent/WO2008020596A2/en
Publication of WO2008020596A3 publication Critical patent/WO2008020596A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/207—Modifications characterised by siRNA, miRNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

The invention features a method for inhibiting growth of a cancer cell by contacting the cell with a composition of an siRNA that inhibits expression of REG4 or KIAA0101. Methods of treating cancer are also within the invention. The invention also features products, including nucleic acid sequences and vectors as well as to compositions comprising them, useful in the provided methods. The invention also provides a method for inhibiting of tumor cell, for example pancreatic cancer cell, prostatic cancer cell, breast cancer cell, and bladder cancer cell, particularly pancreatic ductal adenocarcinoma (PDAC) by inhibiting REG4 gene. The present invention also relates to methods of treating or preventing PDAC in a subject comprising the step of administering to said subject a pharmaceutically effective amount of an antibody or fragment thereof that binds to a protein encoded by REG4. The present invention also relates to methods of diagnosing chemo-radiation therapeutic resistance of a cancer. The present invention also provides therapeutic agents or methods for treating cancer using the polypeptides. The polypeptides of the present invention are composed of an amino acid sequence which comprises polypeptide which comprises QKGIGEFF/SEQ ID NO: 21. The polypeptides of the present invention can be introduced into cancer cells by modifying the polypeptides with transfection agents such as poly-arginine.
PCT/JP2007/065873 2006-08-18 2007-08-08 Treating or preventing cancers over-expressing reg4 or kiaa0101 WO2008020596A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2009524366A JP2010501161A (en) 2006-08-18 2007-08-08 Treatment or prevention of cancers that overexpress REG4 or KIAA0101
CA 2660516 CA2660516A1 (en) 2006-08-18 2007-08-08 Treating or preventing cancers over-expressing reg4 or kiaa0101
BRPI0715763 BRPI0715763A2 (en) 2006-08-18 2007-08-08 treating or preventing cancers by overexpressing reg4 or kiaa0101
EP07792516A EP2059593A2 (en) 2006-08-18 2007-08-08 Treating or preventing cancers over-expressing reg4 or kiaa0101

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US83874906P 2006-08-18 2006-08-18
US83864906P 2006-08-18 2006-08-18
US60/838,649 2006-08-18
US60/838,749 2006-08-18

Publications (2)

Publication Number Publication Date
WO2008020596A2 WO2008020596A2 (en) 2008-02-21
WO2008020596A3 true WO2008020596A3 (en) 2008-06-12

Family

ID=38935815

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/065873 WO2008020596A2 (en) 2006-08-18 2007-08-08 Treating or preventing cancers over-expressing reg4 or kiaa0101

Country Status (7)

Country Link
EP (1) EP2059593A2 (en)
JP (1) JP2010501161A (en)
KR (1) KR20090040391A (en)
BR (1) BRPI0715763A2 (en)
CA (1) CA2660516A1 (en)
RU (1) RU2009109692A (en)
WO (1) WO2008020596A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101196415B1 (en) 2007-01-04 2012-11-02 에스케이케미칼주식회사 Polyarylene sulfide resin with excellent luminosity and preparation method thereof
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
WO2010009271A2 (en) 2008-07-15 2010-01-21 Academia Sinica Glycan arrays on ptfe-like aluminum coated glass slides and related methods
WO2010034487A2 (en) * 2008-09-23 2010-04-01 Silence Therapeutics Ag Means for inhibiting the expression of orc-1
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
AU2011253101A1 (en) * 2010-05-11 2013-01-10 Aveo Pharmaceuticals, Inc. Anti-FGFR2 antibodies
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
EP2885311B1 (en) 2012-08-18 2020-01-01 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
US10086054B2 (en) 2013-06-26 2018-10-02 Academia Sinica RM2 antigens and use thereof
WO2014210564A1 (en) 2013-06-27 2014-12-31 Academia Sinica Glycan conjugates and use thereof
EP3041484B1 (en) 2013-09-06 2021-03-03 Academia Sinica Human inkt cell activation using glycolipids with altered glycosyl groups
KR20160104727A (en) 2014-01-16 2016-09-05 아카데미아 시니카 Compositions and methods for treatment and detection of cancers
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
CN106415244B (en) 2014-03-27 2020-04-24 中央研究院 Reactive marker compounds and uses thereof
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
JP7062361B2 (en) 2014-05-27 2022-05-06 アカデミア シニカ Anti-HER2 sugar-manipulated antibody group and its use
JP7093612B2 (en) 2014-05-27 2022-06-30 アカデミア シニカ Bacteroides-derived fucosidase and how to use it
US11332523B2 (en) 2014-05-28 2022-05-17 Academia Sinica Anti-TNF-alpha glycoantibodies and uses thereof
KR101779147B1 (en) * 2014-07-04 2017-09-20 연세대학교 산학협력단 Compositions for Diagnosing or Treating Pancreatic Cancer Using KIAA1199
JP6899321B2 (en) 2014-09-08 2021-07-07 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Activation of human iNKT cells using glycolipids
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
TW201808978A (en) 2016-03-08 2018-03-16 中央研究院 Methods for modular synthesis of N-glycans and arrays thereof
CN109963868B (en) * 2016-08-22 2023-11-14 醣基生医股份有限公司 Antibodies, binding fragments, and methods of use
RU2759045C1 (en) * 2020-12-22 2021-11-09 Государственное бюджетное учреждение здравоохранения города Москвы городская клиническая больница имени С.П. Боткина департамента здравоохранения города Москвы (ГБУЗ ГКБ им. С.П. Боткина ДЗМ) Method for comprehensive treatment of a locally advanced pancreatic ductal adenocarcinoma

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004003144A2 (en) * 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
WO2004031412A2 (en) * 2002-09-30 2004-04-15 Oncotherapy Science, Inc. Method for diagnosing pancreatic cancer
WO2004092352A2 (en) * 2003-04-14 2004-10-28 Washington University Disruption of the reg pathway
WO2006099539A1 (en) * 2005-03-15 2006-09-21 The Regents Of The University Of California Reg iv: a target for cancer diagnosis and therapy
WO2007102526A1 (en) * 2006-03-02 2007-09-13 Oncotherapy Science, Inc. Methods for diagnosing pancreatic cancer using reg4 protein

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004003144A2 (en) * 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
WO2004031412A2 (en) * 2002-09-30 2004-04-15 Oncotherapy Science, Inc. Method for diagnosing pancreatic cancer
WO2004092352A2 (en) * 2003-04-14 2004-10-28 Washington University Disruption of the reg pathway
WO2006099539A1 (en) * 2005-03-15 2006-09-21 The Regents Of The University Of California Reg iv: a target for cancer diagnosis and therapy
WO2007102526A1 (en) * 2006-03-02 2007-09-13 Oncotherapy Science, Inc. Methods for diagnosing pancreatic cancer using reg4 protein

Non-Patent Citations (25)

* Cited by examiner, † Cited by third party
Title
ARNOLD NICHOLE BOYER ET AL.: "Thioredoxin is downstream of Smad7 in a pathway that promotes growth and suppresses Cisplatin-induced apoptosis in pancreatic cancer", CANCER RESEARCH, vol. 64, May 2004 (2004-05-01), pages 3599 - 3606, XP002466196 *
BISHNUPURI K.S. ET AL.: "Reg IV increases apoptotic resistance and crypt cell survival in a radiation-induced intestinal injury model", GASTROENTEROLOGY, vol. 130, no. 4/suppl.2, April 2006 (2006-04-01), pages A-140 - A-141, XP002466219 *
DENG X. ET AL.: "The kinase Mirk/Dyrk1B mediates cell survival in pancreatic ductal adenocarcinoma", CANCER RESEARCH, vol. 66, no. 8, April 2006 (2006-04-01), pages 4149 - 4158, XP002466190 *
DENICOLA G. AND TUVESON D.A.: "VAV1: a new target in pancreatic cancer ?", CANCER BIOLOGY & THERAPY, vol. 4, no. 5, 2005, pages 509 - 511, XP002466213 *
DUXBURY M.S. ET AL.: "A novel role for Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6 as a determinant of emcitabine chemoresistance in pancreatic adenocarcinoma cells", CANCER RESEARCH, vol. 64, June 2004 (2004-06-01), pages 3987 - 3993, XP002466195 *
DUXBURY M.S. ET AL.: "RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine", ONCOGENE, vol. 23, 2004, pages 1539 - 1548, XP002407219 *
FERNANDEZ-ZAPICO M.E. ET AL.: "Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis", CANCER CELL, vol. 7, 2005, pages 39 - 49, XP002466202 *
HSIAO-HUI FU AND SHIAW-DER YANG: "Suppression of Proline-directed Protein Kinase FA inhibits the malignant growth of human pancreatic ductal adenocarcinoma", ANTICANCER RESEARCH, vol. 24, 2004, pages 1489 - 1494, XP008087819 *
KAYED H. ET AL.: "FXYD3 is overexpressed in pancreatic ductal adenocarcinoma and influences pancreatic cancer cell growth", INTERNATIONAL JOURNAL OF CANCER, vol. 118, January 2006 (2006-01-01), pages 43 - 54, XP002466191 *
KOLB A. ET AL.: "Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions", CANCER BIOLOGY & THERAPY, vol. 4, no. 7, July 2005 (2005-07-01), pages 740 - 746, XP002466199 *
LUO J. ET AL.: "Pancreatic cancer cell-derived Vascular Endothelial Growth Factor is biologically active in vitro and enhances tumorigenicity in vivo", INTERNATIONAL JOURNAL OF CANCER, vol. 92, 2001, pages 361 - 369, XP002466198 *
LUO QIZHI ET AL.: "Silencing of the Regenerating IV (Reg IV) gene by siRNA inhibits the growth and proliferation of human colon adenocarcinomas", GASTROENTEROLOGY, vol. 130, no. 4/suppl.2, April 2006 (2006-04-01), pages A-533, XP002466218 *
NAKAMURA T. ET AL.: "Genome-wide cDNA microarray analysis of gene expression profiles in pancreatic cancers using populations of tumor cells and normal ductal epithelial cells selected for purity by laser microdissection", ONCOGENE, vol. 23, 2004, pages 2385 - 2400, XP002466215 *
NAOHIDE OUE ET AL.: "Expression and localization of Reg IV in human neoplastic and non-neoplastic tissues: Reg IV expression is associated with intestinal and neuroendocrine differentiation in gastric adenocarcinoma", JOURNAL OF PATHOLOGY, vol. 207, 2005, pages 185 - 198, XP002466217 *
NITORI N. ET AL.: "Prognostic significance of Tissue Factor in pancreatic ductal adenocarcinoma", CLINICAL CANCER RESEARCH, vol. 11, no. 7, April 2005 (2005-04-01), pages 2531 - 2539, XP002466200 *
OJI Y. ET AL.: "Overexpression of the Wilms' tumor gene WT1 in pancreatic ductal adenocarcinoma", CANCER SCIENCE, vol. 95, no. 7, July 2004 (2004-07-01), pages 583 - 587, XP002466194 *
SCHNEIDER G. ET AL.: "GADD45alpha is highly expressed in pancreatic ductal adenocarcinoma cells and required for tumor cell viability", INTERNATIONAL JOURNAL OF CANCER, vol. 118, May 2006 (2006-05-01), pages 2405 - 2411, XP002466189 *
SHIMAMURA T.: "Biological and clinicopathological significance of Dysadherin expression in pancreatic cancer", YOKOHAMA MEDICAL JOURNAL, vol. 55, no. 5-6, 2004, pages 471 - 476, XP008087820 *
TAKEHARA A. ET AL: "Novel tumor marker REG4 detected in serum of patients with resectable pancreatic cancer and feasibility for antibody therapy targeting REG4", CANCER SCIENCE, JAPANESE CANCER ASSOCIATION, TOKYO, JP, vol. 97, no. 11, November 2006 (2006-11-01), pages 1191 - 1197, XP002439748, ISSN: 1347-9032 *
TANIUCHI K. ET AL.: "Down-regulation of RAB6KIFL/KIF20A, a Kinesin involved with membrane trafficking of Discs Large Homologue 5, can attenuate growth of pancreatic cancer cell", CANCER RESEARCH, vol. 65, no. 1, January 2005 (2005-01-01), pages 105 - 112, XP002466193 *
TANIUCHI K. ET AL.: "Overexpressed P-cadherin/CDH3 promotes motility of pancreatic cancer cells by interacting with p120ctn and activating Rho-family GTPases", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 65, no. 8, April 2005 (2005-04-01), pages 3092 - 3099, XP002441363, ISSN: 0008-5472 *
VIOLETTE SABINE ET AL.: "Reg IV, a new member of the regenerating gene family, is overexpressed in colorectal carcinomas", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 103, no. 2, 10 January 2003 (2003-01-10), pages 185 - 193, XP002424312, ISSN: 0020-7136 *
WAN M. ET AL.: "SCFbeta-TrCP1 controls Smad4 protein stability in pancreatic cancer cells", AMERICAN JOURNAL OF PATHOLOGY, vol. 166, no. 5, May 2005 (2005-05-01), pages 1379 - 1392, XP002466192 *
WATARU YASUI ET AL.: "Search for new biomarkers of gastric cancer through serial analysis of gene expression and its clinical implications", CANCER SCIENCE, vol. 95, no. 5, May 2004 (2004-05-01), pages 385 - 392, XP002466216 *
YAMAMOTO H. ET AL.: "Expression of Matrix metalloproteinases and tissue inhibitors of Metalloproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of Matrylisin expression", JOURNAL OF CLINICAL ONCOLOGY, vol. 19, no. 4, 2001, pages 1118 - 1127, XP002466201 *

Also Published As

Publication number Publication date
EP2059593A2 (en) 2009-05-20
WO2008020596A2 (en) 2008-02-21
BRPI0715763A2 (en) 2013-09-24
KR20090040391A (en) 2009-04-23
JP2010501161A (en) 2010-01-21
RU2009109692A (en) 2010-09-27
CA2660516A1 (en) 2008-02-21

Similar Documents

Publication Publication Date Title
WO2008020596A3 (en) Treating or preventing cancers over-expressing reg4 or kiaa0101
WO2003105758A3 (en) Cancer-linked gene as target for chemotherapy
WO2003104399A3 (en) Cancer-linked gene as target for chemotherapy
WO2003097803A3 (en) Cancer-linked gene as target for chemotherapy
WO2003101400A3 (en) Cancer-linked gene as target for chemotherapy
MX348154B (en) IL-1ß BINDING ANTIBODIES AND FRAGMENTS THEREOF.
WO2006087637A3 (en) Anti her2/neu antibody
JP2018510881A5 (en)
EP1999149A4 (en) Anti-igf-ir antibodies and uses thereof
WO2005077091A8 (en) Nicotinamide riboside kinase compositions and methods for using the same
JP2012100677A5 (en)
ATE523591T1 (en) USE OF AN RNAI-BASED APPROACH WITH GALECTIN-1 AS A TARGET FOR CANCER TREATMENT
WO2006116322A3 (en) Nicotinamide riboside kinase compositions and methods for using the same
WO2006090810A3 (en) Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides
EP3261678B1 (en) Antibody-urease conjugates for therapeutic purposes
CA2486252A1 (en) Methods for screening for agents that modulate hepatocellular carcinoma development
WO2005083086A3 (en) Epha4 as therapeutic target of prc and pdaca
WO2019055840A1 (en) Chlorotoxin agents and uses thereof
CN102348796B (en) Novel cancer antigen eEF2
AU2017285726B2 (en) Methods for diagnosing and treating metastatic cancer
US20240043557A1 (en) A platform to obtain monoclonal antibodies directed against processed tumor-specific antigens
CN108619516A (en) The inhibitor application in preparation of anti-tumor drugs of HER2-565 nucleic acid fragments and HER2-20KD peptide fragments
WO2003104438A3 (en) Cancer-linked gene as target for chemotherapy
WO2003104401A3 (en) Cancer-linked gene as target for chemotherapy
WO2013163431A1 (en) Diagnosis and treatment of brain tumor

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780038766.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07792516

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2660516

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009524366

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1505/CHENP/2009

Country of ref document: IN

Ref document number: 1020097005475

Country of ref document: KR

Ref document number: 2007792516

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009109692

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0715763

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090218